CapsoVision, Inc. CV
Set alert
6.83 USD -0.11 -1.59%
At close · Oct 30
6.83 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
6.79 Day range 7.10
4.59 52-week range 14.42
- YTD
- -36.11%
- 1 year
- +45.32%
- Open
- 6.99
- Prev close
- 6.94
- Mkt cap
- 363.43M
- Vol
- 86.78K
- Avg vol
- 165.45K
- EPS
- -0.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.79
- High
- 7.10
Financials — quick view
CV Revenue — quarterly 3.64M
CV Net income — quarterly -7.48M
CV EPS — quarterly -0.15
News
- CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
- CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- CapsoVision to Present at the 20th Annual LD Micro Main Event
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)
- CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
- CapsoVision gets FDA clearance for AI Highlights
- CapsoVision Receives FDA Clearance For Its AI Highlights Reading Tool For The CapsoCam Plus System
Your note
Sign in to keep a note on CV — it syncs with the Stock Master app.